Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Study ID
NCT07592585
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VC005 — DRUG
    VC005 Placebo group with Local topical application
  • VC005 Placebo — DRUG
    VC005 Placebo group with Local topical application

Study Details

A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitis

Key Dates

First listed
May 18, 2026
Start date
May 12, 2026
Status verified
Jul 2026
Primary completion
May 30, 2028
Completion
May 30, 2028

Study Design

Enrollment
360 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: VC005 groups
  • Placebo Comparator: VC005 Placebo group

Primary Outcome Measure

Proportion of subjects achieving an Investigator's Global Assessment (IGA) response (defined as an IGA score of 0 or 1 with a reduction of ≥2 points from baseline) [ Time Frame: Week 8 ]

Central Contacts

Find similar trials

Nationwide
Atopic dermatitis / eczema trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies